FY-2023 Revenues increased by 22% at $10.0 million compared to $8.2 million for FY-2022, a $1.8 million increase. Gross margins for FY-2023 up $3.8 million compared to FY-2022 Net loss for FY-2023 of ...
BOUCHERVILLE, Québec, April 30, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma”), a Canadian integrated pharmaceutical company, today reported its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback